By Adriano Marchese
Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial.
Shares rose 93% ahead of the morning bell to $105.22.
The Redwood City, Calif., commercial-stage pharmaceutical company said Monday that its treatment relacorilant in conjuction with the chemotherapy drug nab-paclitaxel met the primary endpoint of the Rosella trials, showing improved progression-free survival in patients with platinum-resistant ovarian cancer.
The data showed that patients treated with the combination of relacorilant and chemotherapy experienced a 30% reduction in risk of disease progression compared with patients treated with nab-paclitaxel alone.
Patients with advanced ovarian cancer have had few adequate treatment options, said Alexander Olawaiye, principal investigator in the trial and director of gynecological cancer research at Magee-Women's Hospital of the University of Pittsburgh. He said patients with recurrent forms of the disease eventually develop resistance to available therapies.
"The improvement in survival seen in Rosella, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer," Chief Development Officer Bill Guyer said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 31, 2025 08:55 ET (12:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。